SeaCrest Wealth Management’s Adicet Bio ACET Stock Holding History

SeaCrest Wealth Management’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-87	Closed	-$67K	–	528
2019 Q1	$67K	Buy	+87	New	+$79.1K	0.01%	832

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SCM

Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SeaCrest Wealth Management's ACET Position: Q2 2019 in Review

SeaCrest Wealth Management sold out of Adicet Bio (ACET) in Q2 2019, closing a stake of 87 shares — an estimated $67K sold.

SeaCrest Wealth Management first reported a position in ACET in Q1 2019 and held it in 1 quarter. The position peaked at $67K in Q1 2019. 48 funds tracked by Wall St. Rank hold ACET as of Q2 2019.

SeaCrest Wealth Management reported no remaining Adicet Bio position as of Q2 2019 after selling out during the quarter.
SeaCrest Wealth Management sold 87 Adicet Bio shares in Q2 2019, an estimated $67K.
SeaCrest Wealth Management first reported a position in Adicet Bio in Q1 2019 and held it in 1 quarter.
SeaCrest Wealth Management's Adicet Bio position peaked at $67K in Q1 2019.
48 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2019.

Based on SeaCrest Wealth Management's 13F filing for Q2 2019, filed 19 Jul 2019.